Home > Rheumatology > ACR 2020 > Late-Breaking News > Gout treatment with febuxostat: no higher cardiovascular mortality

Gout treatment with febuxostat: no higher cardiovascular mortality

Presented By
Prof. Thomas MacDonald, University of Dundee, UK
Conference
ACR 2020
Trial
CARES, FAST
A new evaluation of the risk for cardiovascular safety under treatment with febuxostat within a post-licensing study demonstrated no higher rates of cardiovascular mortality and major cardiovascular events when compared to allopurinol. The current post-authorisation study was initiated as suggested by the EMA to obtain data about the cardiovascular (CV) safety of febuxostat in comparison to allopurinol, 2 possible treatments for hyperuricaemia [1]. Previously, the CARES trial (NCT01101035) had raised concerns regarding CV risk with febuxostat that led to changes in treatment recommendations [1,2]. However, given that CV disease risk factors are common in patients with gout, lingering doubts about ascribing such a CV risk to febuxostat persisted. The FAST trial (ISRCTN72443728)...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on